Status:

COMPLETED

National, Multicenter PMS Study "Patient Reported Outcome" in Breast Reconstruction Following Mastectomy With TiLOOP Bra

Lead Sponsor:

Pfm Medical Mepro Gmbh

Collaborating Sponsors:

pfm medical gmbh

Conditions:

Breast Reconstruction After Mastectomy

Eligibility:

FEMALE

18-70 years

Phase:

NA

Brief Summary

This multicentre, non-randomised, observational clinical device investigation will be performed to obtain postmarketing information on the TiLOOP® Bra and in particular on the improvement of the patie...

Eligibility Criteria

Inclusion

  • The TiLOOP®Bra is designed to assist oncologically indexed skin sparing mastectomy or subcutaneous mastectomy with preservation of the nipple-areola-complex during primary breast reconstruction, secondary breast reconstruction or corrective breast surgery. Patients shall be included if they meet all of the following criteria:
  • Clinical Criteria (reason):
  • women with indication of prophylactic operation or oncoplastic operation with support of a mesh implant
  • women with histologically confirmed breast cancer or precancerosis or genetic pre-existing conditions with increased risk of breast cancer or with a family history
  • the health of women must comply with ECOG (Eastern Cooperative Oncology Group) performance status 0-2
  • Study-related inclusion criteria - Legal reasons:
  • Patient is mentally able to understand the nature, aims, or possible consequences of the clinical investigation
  • Patient information has been handed out and all written consents are at hand.
  • Patient is between 18 and 70 years old.

Exclusion

  • Patients must be excluded if any of the following conditions exist or cannot be excluded:
  • Device-related exclusion criteria (contraindications):
  • Pathological or physical condition precluding such as:
  • Pregnancy or breast-feeding patients
  • Known intolerance to the mesh-implants under investigation.
  • Study-related exclusion criteria - Medical reasons:
  • metastatic breast cancer
  • medicamentous regulated diabetes with blood sugar level \>250
  • inadequate bone marrow function with neutrophil granulocytes \<1500 and blood plates \< 10000/µl
  • patient with known contraindication to mesh-implants or plastic-reconstructive breast operations
  • Study-related exclusion criteria - Legal reasons:
  • Lack of written patients informed consent.
  • Lack of patient compliance regarding data collection, treatment or follow-up investigations in the scope of the protocol.
  • Patient is institutionalized by court or official order (MPG§20.3).
  • Participation in another operative clinical investigation.
  • It is thought that the study-related exclusion criteria will not significantly influence the sample of the population under investigation.

Key Trial Info

Start Date :

November 1 2013

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 1 2021

Estimated Enrollment :

267 Patients enrolled

Trial Details

Trial ID

NCT01885572

Start Date

November 1 2013

End Date

June 1 2021

Last Update

September 20 2021

Active Locations (8)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (8 locations)

1

Charite Campus Mitte and Benjamin Franklin

Berlin, Germany, 10117

2

St. Gertrauden Krankenhaus

Berlin, Germany, 10713

3

Vivantes Kliniken am Urban

Berlin, Germany, 10967

4

Helios Kliniken

Berlin, Germany, 13125